Lucid Diagnostics Highlights Promising EsoGuard Study Results

Lucid Diagnostics (LUCD) has provided an announcement.

Lucid Diagnostics Inc. has announced the publication of promising data from a study sponsored by the National Cancer Institute, showcasing the effectiveness of its EsoGuard Esophageal DNA Test with the EsoCheck Cell Collection Device. This breakthrough is expected to spark interest among investors as it highlights the company’s potential in the growing field of medical diagnostics.

See more data about LUCD stock on TipRanks’ Stock Analysis page.